Cryostorage facility launches new entity to provide IVF clinics with ‘holistic’ cryostorage solution

A US cryostorage facility has launched a new entity specialising in providing IVF clinics with an “end-to-end” cryostorage solution.
ReproTech has announced the launch of Cryo-Logix as a separate entity within the company, with a focus on enabling IVF clinics to provide better care to their patients.
Cryo-Logix claims to utilise clinic EMR data to ensure streamlined communication between systems. According to ReproTech, complimentary transport of specimens to and from IVF clinics will also be available as a service to help ensure there are no interruptions for patients preparing for treatment.
The Cryo-Logix’s team, the company says, will help to alleviate the administrative burdens that many IVF clinics face by taking responsibility for invoicing, collections, patient outreach, logistics and disposition for cryogenic inventory whether it is stored at the IVF clinic tank or at ReproTech.
Brad Senstra, chief executive officer at ReproTech, said: “IVF clinics have been searching for a best-in-class end-to-end cryostorage solution that reduces the risks of storing human tissue on-site at fertility clinics.
“As the undisputed experts in long-term cryogenic storage, we created Cryo-Logix to meet this critical need and to provide peace of mind for clinic staff who wake up every day with the singular goal of helping to ensure that their patients receive the highest levels of care and treatment.”
ReproTech has previously worked with multiple of clinics in the US, including private IVF practices and large university and hospital IVF programmes, providing storage for thousands of human specimens via disaster-proof safe storage rooms that are purpose built for all natural disasters.
The company says it has multi-layer monitoring and redundant proprietary systems in place to protect precious reproductive tissue specimens.
To receive the Femtech World newsletter, sign up here.
Newsletter
Sign up for free weekly updates
The latest femtech news, research and investment, straight to your inbox.









